McKesson (MCK) 10-K Summary — Year Ended Mar 31, 2023
McKesson, a diversified healthcare services leader, reported revenue growth and increased profitability for the period. The company also generated strong operating cash flow.
Key takeaway
Year ended Mar 31, 2023 · FY2025 10-K
McKesson, a diversified healthcare services leader, reported revenue growth and increased profitability for the period. The company also generated strong operating cash flow.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$276.7B
Revenue reported for the fiscal year.
Operating income
$4.4B
Income from operations reported for the year.
Net income
$3.6B
Net income reported for the year.
Operating cash flow
$5.2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2022 | $264B | n/a |
| Mar 31, 2023 | $276.7B | +4.8% |
Business overview
McKesson traces its roots to 1833 and operates as a diversified healthcare services leader. It partners with biopharma companies, care providers, pharmacies, and governments to deliver insights, products, and services that make quality care more accessible and affordable. The company's segments include U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.
Financial performance
Revenue and net income both increased compared to the prior year. Operating cash flow was strong, supporting the company's financial position.
Material risks
The filing includes a risk factors section, but the supplied context does not contain specific descriptions of those risks. Therefore, no material risks can be identified from the provided text.
Liquidity and capital
The company used operating cash flow to fund share repurchases, which reduced its weighted-average diluted share count. This capital allocation approach impacted reported earnings per share.
What to watch
The pace and scale of share repurchases should be monitored in the next filing, as they directly affect earnings per share.